CLINICAL_TRIALS trial_result · 2014-04-21

Clinical Trial Update: Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma [Phase 2]

A Phase 2 trial evaluating imatinib (Gleevec) in patients with anaplastic thyroid carcinoma was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Thyroid Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-04-21